TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Shares Shorted: Short Interest Down 47.7% in September

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 9,356 shares, a decline of 47.7% from the September 15th total of 17,898 shares. Based on an average daily volume of 2,596 shares, the days-to-cover ratio is presently 3.6 days.

TriSalus Life Sciences Stock Performance

Shares of TLSIW traded down $0.01 during trading hours on Friday, reaching $0.89. 8,598 shares of the company’s stock traded hands, compared to its average volume of 4,968. TriSalus Life Sciences has a 12 month low of $0.44 and a 12 month high of $1.85. The firm’s 50 day simple moving average is $0.90 and its 200-day simple moving average is $0.84.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp purchased a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 610,963 shares of the company’s stock, valued at approximately $2,780,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused medical technology and therapeutics company developing products intended to improve the treatment of solid tumors, particularly cancers of the liver and pancreas. The company’s approach is designed to address the biological and physical barriers that can limit the delivery of therapies into tumors.

Its primary technology is Pressure-Enabled Drug Delivery (PEDD), which uses specialized infusion systems to administer treatments directly to tumors or tumor-feeding blood vessels.